30
Participants
Start Date
July 31, 2021
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2026
Oncoquest-L vaccine
Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
Southeastern Regional Medical Center at CTCA, Newnan
XEME Biopharma Inc.
INDUSTRY